- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
News and Views in Healthcare: This Weekend's Top 3 Reads
What's on our radar in the healthcare world.
Our Top 3 Reads for Today:
1. The Republican-led Congress, under pressure from President-elect Donald Trump to act quickly, made the first move toward scrapping Obamacare on Thursday. The nonpartisan Committee for a Responsible Federal Budget said earlier this month that repealing President Barack Obama's signature health insurance law in its entirety would cost roughly $350 billion over the next decade. Republicans say a good Obamacare replacement strategy would reduce government spending, but they have not agreed on a consensus plan.
2. Mylan gets competition in the form of a generic-version of Epipen from CVS. At one-sixth of the original price. Health insurance giant Cigna announced this week it's dropping coverage for name brand $600 EpiPens, just as drugstore chain CVS nearly halved the price of a rival epinephrine autoinjector, Adrenaclick, to $109.
3. The Biologics Prescribers Collaborative (BPC) has voiced to FDA that they are concerned with "random" suffixes for biosimilars naming guidance. As physicians who routinely prescribe biologic medicines, they believe a memorable suffix is needed; although, it is still considered a win for patients and physicians because distinguishable naming is essential for pharmacovigilance, patient safety and transparency.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.
